Options Trading for Omnicell (OMCL) in the First Week of August 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Should l Buy OMCL?
Source: NASDAQ.COM
Put Contract Overview: The $45.00 put contract for OMCL has a bid of $5.40, allowing investors to buy shares at a cost basis of $39.60, which is attractive compared to the current price of $46.38. There is a 63% chance the contract may expire worthless, potentially yielding a 12% return on cash commitment.
Call Contract Overview: The $55.00 call contract has a bid of $3.80, offering a total return of 26.78% if the stock is called away by August 2026. This strike price is 19% above the current stock price, with a 54% chance of expiring worthless, which would provide an 8.19% additional return.
Volatility Insights: The implied volatility for the put contract is 56% and for the call contract is 55%, while the actual trailing twelve-month volatility is calculated at 44%, indicating a stable trading environment for OMCL.
YieldBoost Concept: The article discusses the concept of YieldBoost, highlighting potential returns from both put and call contracts, and encourages investors to track these options and their changing odds on Stock Options Channel's website.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OMCL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OMCL
Wall Street analysts forecast OMCL stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 38.280
Low
46.00
Averages
54.20
High
63.00
Current: 38.280
Low
46.00
Averages
54.20
High
63.00
About OMCL
Omnicell, Inc. is a healthcare technology provider focused on autonomous medication management, by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that are helping to improve efficiency and enhance patient safety for healthcare facilities. The Company is focused on helping its customers define and deliver a medication management strategy designed for pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. It provides a range of points of care medication and supplies dispensing systems, including automated systems and offers advanced automation solutions, including robotics designed to automate work, streamline workflows, and reduce human error. It provides central pharmacy automation solutions for both medication dispensing and IV compounding and provides patient engagement solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pharmaceutical Industry Accelerates AI Compliance Transformation
- Real-Time Compliance Monitoring: Pharmaceutical companies are embedding artificial intelligence into production processes to enable real-time compliance monitoring, replacing traditional batch testing and manual oversight, thereby enhancing production efficiency and reducing human error risks.
- Regulatory Push for Automation: Increasingly stringent expectations from global regulatory agencies regarding data integrity and traceability are accelerating the pharmaceutical industry's shift toward automation to improve compliance and reduce operational risks, with Oncotelic Therapeutics exemplifying this trend.
- Rise of Pharma 4.0 Concept: The implementation of Pharma 4.0 integrates digital technologies with production ecosystems, enhancing flexibility and decision-making capabilities, as industry giants like Pfizer and Johnson & Johnson actively adopt AI and digital manufacturing technologies to drive overall production efficiency improvements.
- Cost Reduction in Development: The cost of bringing a new drug to market can exceed billions, and AI-driven automation systems help pharmaceutical companies reduce variability and improve process reliability through real-time data analysis and continuous monitoring, thereby lowering development risks and costs.
See More
Omnicell Advances Vision of Autonomous Pharmacy Amid Challenges
- Vision for Autonomous Pharmacy: Omnicell is committed to advancing the industry-defined vision of the autonomous pharmacy, aiming for zero-error medication management by enhancing operational efficiencies, having expanded from a single-point solution to a diversified product platform over recent years, thereby strengthening its market competitiveness.
- Expansion of SaaS and Expert Services: The company is steadily increasing revenue from its SaaS and Expert Services through acquisitions and new platform launches, with several health systems committing to its inventory optimization service in Q4 2025, indicating robust market demand.
- Strong Financial Health: As of Q4 2025, Omnicell reported cash and cash equivalents of $197 million against total debt of $168 million, reflecting a solid solvency position with a debt-to-capital ratio reduced to 12.1%, which supports future investments and expansion.
- Cost Pressures Impacting Margins: Despite successes in various sectors, Omnicell faced challenges from labor shortages and rising raw material costs, leading to a year-over-year decline of approximately 4 percentage points in non-GAAP gross margin in Q4 2025, which may strain profit margins.
See More
Omnicell Reports Strong Q4 2025 Earnings and Outlook
- Strong Financial Performance: Omnicell reported total revenue of $314 million for Q4 2025, reflecting a 2% increase from Q4 2024, indicating sustained demand and solid execution in the medication management sector.
- Annual Recurring Revenue Growth: The company exited 2025 with an annual recurring revenue (ARR) of $636 million, a 10% increase year-over-year, showcasing strong customer demand for new products, particularly Titan XT and the OmniSphere platform.
- Optimistic Outlook: Management expects total revenue for Q1 2026 to be between $300 million and $310 million, with full-year revenue projected at $1.215 billion to $1.255 billion, demonstrating confidence in future market conditions.
- Enhanced Market Competitiveness: The successful launch of Titan XT and positive market feedback are expected to drive market share growth in medication management, especially with a replacement cycle opportunity exceeding $2.5 billion.
See More
Omnicell Q4 Earnings Report Analysis
- Earnings Performance: Omnicell reported a Q4 non-GAAP EPS of $0.40, missing estimates by $0.10, indicating pressure on profitability, while revenue of $314 million, up 2.3% year-over-year, slightly exceeded market expectations by $640,000, reflecting the company's stability in the market.
- Declining EBITDA: The non-GAAP EBITDA for Q4 2025 was $37 million, down from $46 million in Q4 2024, suggesting challenges in cost control and profitability that may impact future investor confidence and stock performance.
- Drop in Product Bookings: As of December 31, 2025, Omnicell's product bookings were $535 million, a 4% year-over-year decline primarily due to the late stage of the XT upgrade cycle, indicating weakening market demand that could affect future revenue growth.
- 2026 Guidance: Omnicell's guidance for 2026 indicates expected product bookings between $510 million and $560 million and annual recurring revenue between $680 million and $700 million, although overall revenue expectations exceed market consensus, ongoing market conditions will need to be monitored for their potential impact on performance.
See More
Omnicell Reports Strong Q4 2025 Financial Results and Launches Titan XT
- Strong Financial Performance: Omnicell reported total revenues of $314 million for Q4 2025, a 2% increase from Q4 2024, driven by robust technical service and SaaS revenues, indicating the company's sustained growth potential in medication management.
- Annual Revenue Growth: The total revenue for the year 2025 reached $1.185 billion, up 7% year-over-year, reflecting strong demand for connected devices and technical services, which underscores the company's solid market position and confidence in future growth.
- New Product Launch: At the 2025 ASHP meeting, Omnicell unveiled Titan XT, aimed at enhancing medication management efficiency by integrating automation with intelligent technology, expected to strengthen the company's competitive edge in healthcare systems to meet rising market demands.
- Positive Future Outlook: The company anticipates total revenues for 2026 to range between $1.215 billion and $1.255 billion, demonstrating confidence in future growth while planning to achieve sustainable profitability through ongoing innovation and market expansion.
See More
Bank of America Upgrades Omnicell to Buy with Price Target Increase
- Rating Upgrade: Bank of America upgraded Omnicell (OMCL) from Neutral to Buy and raised its price target from $53 to $70, indicating analyst optimism ahead of the company's Q4 2025 results.
- Market Leadership: Omnicell dominates the market for automated dispensing cabinets in hospitals, and analyst Allen Lutz noted the launch of its first new cabinet since 2017, which could further solidify its market position.
- Revenue Growth Outlook: Although the analyst projects a 3%-4% CAGR in connected device revenue through 2028, this is still indicative of the company's potential for future growth compared to mid-teens growth in the previous cycle.
- Investment Opportunity: The analyst believes that Omnicell's initial 2026 guidance may only reflect modest contributions in the second half of this year, viewing any weakness as a buying opportunity, which demonstrates confidence in the company's long-term growth trajectory.
See More
Pharmaceutical Industry Accelerates AI Compliance Transformation
- Real-Time Compliance Monitoring: Pharmaceutical companies are embedding artificial intelligence into production processes to enable real-time compliance monitoring, replacing traditional batch testing and manual oversight, thereby enhancing production efficiency and reducing human error risks.
- Regulatory Push for Automation: Increasingly stringent expectations from global regulatory agencies regarding data integrity and traceability are accelerating the pharmaceutical industry's shift toward automation to improve compliance and reduce operational risks, with Oncotelic Therapeutics exemplifying this trend.
- Rise of Pharma 4.0 Concept: The implementation of Pharma 4.0 integrates digital technologies with production ecosystems, enhancing flexibility and decision-making capabilities, as industry giants like Pfizer and Johnson & Johnson actively adopt AI and digital manufacturing technologies to drive overall production efficiency improvements.
- Cost Reduction in Development: The cost of bringing a new drug to market can exceed billions, and AI-driven automation systems help pharmaceutical companies reduce variability and improve process reliability through real-time data analysis and continuous monitoring, thereby lowering development risks and costs.
See More
Omnicell Advances Vision of Autonomous Pharmacy Amid Challenges
- Vision for Autonomous Pharmacy: Omnicell is committed to advancing the industry-defined vision of the autonomous pharmacy, aiming for zero-error medication management by enhancing operational efficiencies, having expanded from a single-point solution to a diversified product platform over recent years, thereby strengthening its market competitiveness.
- Expansion of SaaS and Expert Services: The company is steadily increasing revenue from its SaaS and Expert Services through acquisitions and new platform launches, with several health systems committing to its inventory optimization service in Q4 2025, indicating robust market demand.
- Strong Financial Health: As of Q4 2025, Omnicell reported cash and cash equivalents of $197 million against total debt of $168 million, reflecting a solid solvency position with a debt-to-capital ratio reduced to 12.1%, which supports future investments and expansion.
- Cost Pressures Impacting Margins: Despite successes in various sectors, Omnicell faced challenges from labor shortages and rising raw material costs, leading to a year-over-year decline of approximately 4 percentage points in non-GAAP gross margin in Q4 2025, which may strain profit margins.
See More
Omnicell Reports Strong Q4 2025 Earnings and Outlook
- Strong Financial Performance: Omnicell reported total revenue of $314 million for Q4 2025, reflecting a 2% increase from Q4 2024, indicating sustained demand and solid execution in the medication management sector.
- Annual Recurring Revenue Growth: The company exited 2025 with an annual recurring revenue (ARR) of $636 million, a 10% increase year-over-year, showcasing strong customer demand for new products, particularly Titan XT and the OmniSphere platform.
- Optimistic Outlook: Management expects total revenue for Q1 2026 to be between $300 million and $310 million, with full-year revenue projected at $1.215 billion to $1.255 billion, demonstrating confidence in future market conditions.
- Enhanced Market Competitiveness: The successful launch of Titan XT and positive market feedback are expected to drive market share growth in medication management, especially with a replacement cycle opportunity exceeding $2.5 billion.
See More
Omnicell Q4 Earnings Report Analysis
- Earnings Performance: Omnicell reported a Q4 non-GAAP EPS of $0.40, missing estimates by $0.10, indicating pressure on profitability, while revenue of $314 million, up 2.3% year-over-year, slightly exceeded market expectations by $640,000, reflecting the company's stability in the market.
- Declining EBITDA: The non-GAAP EBITDA for Q4 2025 was $37 million, down from $46 million in Q4 2024, suggesting challenges in cost control and profitability that may impact future investor confidence and stock performance.
- Drop in Product Bookings: As of December 31, 2025, Omnicell's product bookings were $535 million, a 4% year-over-year decline primarily due to the late stage of the XT upgrade cycle, indicating weakening market demand that could affect future revenue growth.
- 2026 Guidance: Omnicell's guidance for 2026 indicates expected product bookings between $510 million and $560 million and annual recurring revenue between $680 million and $700 million, although overall revenue expectations exceed market consensus, ongoing market conditions will need to be monitored for their potential impact on performance.
See More
Omnicell Reports Strong Q4 2025 Financial Results and Launches Titan XT
- Strong Financial Performance: Omnicell reported total revenues of $314 million for Q4 2025, a 2% increase from Q4 2024, driven by robust technical service and SaaS revenues, indicating the company's sustained growth potential in medication management.
- Annual Revenue Growth: The total revenue for the year 2025 reached $1.185 billion, up 7% year-over-year, reflecting strong demand for connected devices and technical services, which underscores the company's solid market position and confidence in future growth.
- New Product Launch: At the 2025 ASHP meeting, Omnicell unveiled Titan XT, aimed at enhancing medication management efficiency by integrating automation with intelligent technology, expected to strengthen the company's competitive edge in healthcare systems to meet rising market demands.
- Positive Future Outlook: The company anticipates total revenues for 2026 to range between $1.215 billion and $1.255 billion, demonstrating confidence in future growth while planning to achieve sustainable profitability through ongoing innovation and market expansion.
See More
Bank of America Upgrades Omnicell to Buy with Price Target Increase
- Rating Upgrade: Bank of America upgraded Omnicell (OMCL) from Neutral to Buy and raised its price target from $53 to $70, indicating analyst optimism ahead of the company's Q4 2025 results.
- Market Leadership: Omnicell dominates the market for automated dispensing cabinets in hospitals, and analyst Allen Lutz noted the launch of its first new cabinet since 2017, which could further solidify its market position.
- Revenue Growth Outlook: Although the analyst projects a 3%-4% CAGR in connected device revenue through 2028, this is still indicative of the company's potential for future growth compared to mid-teens growth in the previous cycle.
- Investment Opportunity: The analyst believes that Omnicell's initial 2026 guidance may only reflect modest contributions in the second half of this year, viewing any weakness as a buying opportunity, which demonstrates confidence in the company's long-term growth trajectory.
See More
